Results 111 to 120 of about 186,499 (128)
Some of the next articles are maybe not open access.

Comparing developmental outcomes of children with CLN2 disease receiving cerliponase alfa to a natural history cohort

Molecular Genetics and Metabolism, 2021
Jessica Scherr   +2 more
openaire   +1 more source

Cerliponase Alfa for the Treatment of CLN2 Disease in a Patient Cohort Including Children under 3 Years

Neuropediatrics, 2023
A. Schulz   +6 more
openaire   +1 more source

Intracerebroventricular cerliponase alfa for CLN2 disease: Clinical practice considerations from US clinics

Molecular Genetics and Metabolism, 2020
Raymond Y. Wang   +17 more
openaire   +1 more source

Longitudinal serial brain MRI volumetrics and DTI analysis in atypical CLN2 patients treated with cerliponase alfa

Ceroid Lipofuscinosis Type 2 (CLN2) is caused by inherited tripeptidyl peptidase 1 (TPP1) enzyme deficiency. The main treatment is a biweekly intracerebroventricular enzyme replacement therapy (ICV-ERT) of recombinant human TPP1 (cerliponase alfa).
Harriet Chang   +5 more
openaire   +1 more source

Seizures and Movement Disorders in Patients with CLN2 Disease Treated with Cerliponase Alfa in the Real-World Setting

Neuropediatrics
Angela Schulz   +10 more
openaire   +1 more source

Home - About - Disclaimer - Privacy